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No overall increased risk of lymphoma associated with antibodies to human herpesvirus-8 was found in 526 lymphomas and 599
controls (odds ratio (OR)¼ 1.04, 95% confidence interval (CI)¼ 0.62–1.75); significant increases were noted for 19
lymphoplasmacytic lymphomas (OR¼ 4.47, 95% CI¼ 1.34–14.85) and nine low-grade lymphoma/lymphoma B-cell NOS
(OR¼ 5.82, 95% CI¼ 1.07–31.73).
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Kaposi’s sarcoma (KS)-associated herpesvirus, also known as
human herpesvirus-8 (HHV-8), has been shown to be causally
associated with KS, primary effusion lymphoma (PEL) and
multicentric Castleman’s disease (MCD) (Chang et al, 1994;
Soulier et al, 1995; Cesarman et al, 1996). The three conditions
are increased in immunocompromised states, as in human
immunodeficiency virus (HIV) infection. The association of
HHV-8 with other lymphoproliferative disorders in non-HIV-
infected subjects remains controversial (Mikala et al, 1999). In the
absence of HIV, HHV-8 DNA has been detected in T-cell PEL cells
(Lechapt-Zalcman et al, 2001) and in lymphoma cells with
plasmacytic differentiation, but not in cutaneous T- and B-cell
lymphoma (Dupin et al, 1997) or in mycosis fungoides (Henghold
et al, 1997).
A systematic serological evaluation of HHV-8 in HIV serone-
gative cancer patients failed to identify a significantly increased
prevalence among patients with lymphoid neoplasms (Sitas et al,
1999). A similar study design in Uganda identified a slightly higher
HHV-8 prevalence among patients with non-Hodgkin lymphoma
(61%) and Hodgkin lymphoma (61%) as compared to the control
population (50%). Differences were not statistically significant
(Newton et al, 2003).
In this study, in Spain, we evaluated the association between
HHV-8 infection and malignant lymphoma.
MATERIALS AND METHODS
The study subjects were recruited at four centres in Spain:
Barcelona, two in Tarragona (Tortosa and Reus) and Madrid.
Cases were consecutive patients newly diagnosed with a lymphoid
malignancy between 1998 and 2002 and categorised according to
the WHO Classification for Neoplastic Diseases of the Lymphoid
Tissues (Jaffe et al, 2003). Controls were randomly selected from
the hospital wards and outpatient clinics daily lists and
synchronically identified with the cases. Controls were frequency
matched to the cases by age, sex and study centre. Subjects with
cancer, organ transplant and/or systemic infection as main
diagnosis were not eligible as controls.
All included subjects were interviewed on demographic, medical
and family history, and environmental exposures. Cases and
controls provided a blood sample. Informed consent was obtained
from all subjects prior to enrolment, and the Institutional Review
Boards of the participating centres approved the study.
Of 700 eligible cases, 526 (75%) were included in the study, 28
refused to participate, 25 died before the interview, 116 did not
provide a blood sample and five cases had no interview. Of 655
eligible controls, 599 (91.6%) were included in the study, 23 refused
to participate and 33 did not provide a blood sample. Further details
of the study have been described elsewhere (de Sanjose et al, 2004).
HHV-8 antibody and HIV detection
Antibodies against the lytic antigent K8.1 were tested using a
enzyme-linked immunoassay (ELISA) as described previously (de
Sanjose et al, 2002). Samples with optical densities (OD) below 1
were considered to be negative. Antibodies against the open-
reading frame 73 (LANA) were tested by a similar ELISA using
full-length baculo expressed LANA as antigen and serum diluted
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1 : 100. Optical densities values below 0.8 were considered to be
negative. All the sera were tested blind to the disease status.
HIV infection status was determined by testing the sera with a
licensed commercial ELISA (Abbot Diagnostics, North Chicago, IL,
USA). All positive subjects were confirmed with Western blot.
HHV-8 quantitative real-time PCR
Peripheral blood mononuclear cells (PBMC) were tested for HHV-
8 DNA by quantitative PCR in all subjects considered to be
seropositive for either anti-K8.1 or anti-LANA as described
previously (de Sanjose et al, 2002). DNA quality and cell
quantitation was determined using real-time PCR for endogenous
retrovirus 3 (Yuan et al, 2001).
Statistical analyses
Unconditional logistic regression was used to estimate the odds
ratios (OR) and 95% confidence interval (95% CI) in order to
measure the association between specific variables and the risk of
lymphoma. Questionnaire variables were explored for their
association with HHV-8 or with case–control status at Po0.10
and considered for inclusion in the regression model. The
contribution to the models by other potential confounding
variables was tested by means of the likelihood ratio test.
RESULTS
The study population consisted of 526 lymphoma cases and 599
controls. The average age at entry was 59.7 years among cases and
58.0 years among controls.
No differences were observed in the distribution of cases and
controls in relation to age, sex, recruitment area, educational level
and history of blood transfusion (Table 1). Of all the items
explored, low educational level was significantly associated with
higher prevalence of HHV-8 among controls, but the educational
level did not modify the overall risk estimates (data not shown).
HIV infection was detected in 17 cases and one control, while
eight cases had a history of organ transplant. HHV-8 was detected
in four of these subjects (15.4%). These patients are excluded in
the following results if not otherwise specified.
In all, 32 controls (5.4%) and 29 cases (5.8%) were HHV-8
positive (Table 2). HHV-8 seroprevalence was similar for cases and
Table 1 Distribution of cases and controls by sociodemographic
characteristics
Controls Lymphoma cases
Number (%) Number (%)
Total 600 (100) 529 (100)
Age (years)
o43 130 (21.7) 95 (18.0)
43–56 123 (20.5) 106 (20.0)
57–67 124 (20.7) 106 (20.6)
68–74 114 (19) 124 (23.6)
474 108 (18) 95 (18.1)
Sex
Males 312 (52.1) 287 (54.6)
Females 287 (47.9) 239 (45.4)
Recruitment area
Barcelona 500 (83.3) 411 (78.1)
Madrid 55 (9.2) 68 (12.9)
Tarragona 44 (7.3) 47 (8.9)
Educational level attained
Primary 237 (39.6) 212 (40.3)
Secondary 60 (10.0) 39 (7.4)
Higher school 17 (2.8) 20 (3.8)
University 41 (6.8) 44 (8.4)
Other 38 (6.3) 33 (6.3)
No degree 138 (23.0) 110 (20.9)
Never school 61 (10.2) 67 (12.7)
History of blood transfusion 160 (26.7) 129 (24.5)
Table 2 OR for HHV-8 (K8.1 or LANA) detection among lymphoma categories and age–sex matched controlsa
Total, N K8.1, N+ (%) LANA, N+ (%) K8.1 or LANA, N+ (%) ORb (95% CI)
Controls 598 24 (4) 17 (2.8) 32 (5.4) Ref
All lymphoid neoplasm 501 43 (8.6) 16 (3.2) 29 (5.8) 1.04 (0.62–1.75)
B-cell lymphomas 464 22 (4.7) 15 (3.2) 27 (5.8) 1.03 (0.60–1.76)
Chronic lymphocytic leukaemia 115 6 (5.2) 3 (2.6) 7 (6.1) 1.16 (0.48–2.79)
Lymphoplasmacytic lymphoma 19 4 (21.1) 1 (5.3) 4 (21.1) 4.47(1.34–14.85)
Marginal zone 25 0 (0) 0 (0) 0 (0) NA
Splenic marginal zone 26 3 (11.5) 1 (3.8) 3 (11.5) 2.50 (0.68–9.14)
Plasma cell myeloma 70 2 (2.9) 2 (2.9) 2 (2.9) 0.53 (0.12–2.30)
Follicular lymphoma 37 1 (2.7) 0 (0) 1 (2.7) 0.46 (0.06–3.57)
Diffuse large B cell 82 3 (3.7) 3 (3.7) 5 (6.1) 1.08 (0.40–2.89)
Low-grade B and lymphoma B nos. 9 2 (22.2) 2 (22.2) 2 (22.2) 5.82 (1.07–31.73)
Other B-cell lymphomac 25 0 (0) 0 (0) 0 (0) NA
Hodgkin lymphoma 56 1 (1.8) 2 (3.6) 3 (5.4) 0.97 (0.27–3.43)
T-cell lymphomas 37 1 (2.7) 1 (2.8) 2 (5.4) 1.02 (0.23–4.50)
Mycosis fungoides/sezary 16 0 (0) 1 (6.7) 1 (6.3) 1.56 (0.19–12.94)
Other T celld 21 1 (4.8) 0 (0) 1 (4.8) 0.84 (0.11–6.57)
aExcluded one control and 17 lymphoma cases HIV positive and eight lymphoma cases organ allograph recipients. bOR adjusted age, sex and centre of recruitment. cOther B-cell
lymphoma includes: nine, mantle lymphoma; two, hairy cell; one, Burkitt; three, high-grade lymphoma; nine, precursor B lymphoblastic lymphoma/leukaemia; one, high-grade
lymphoma. dOther T-cell lymphoma includes: large granular lymphocytic leukaemia; two, peripheral T-cell lymphomas, unspecified; three, angioimmunoblastic T-cell lymphoma;
three, angiocentric lymphoma; eight, anaplastic large-cell lymphoma CD30+; one, lymphoma T not otherwise specified, which was the only one HHV8 positive. OR¼ odds ratio;
HHV-8¼ human herpesvirus-8; CI¼ confidence interval, HIV¼ human immunodeficiency virus. NA¼ not applicable.
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controls (OR¼ 1.04, 95% CI¼ 0.62– 1.75). Within B-cell lympho-
mas, HHV-8 infection was associated with an increased risk of
lymphoplasmacytic lymphoma (OR¼ 4.47, 95% CI¼ 1.34– 14.85)
and of low-grade B-cell lymphoma not otherwise specified (NOS)
and lymphoma NOS (OR¼ 5.82, 95% CI¼ 1.07–31.73).
HHV-8 DNA was identified in nine of 69 (13.0%) HHV-8
seropositive subjects, including those HIV-infected subjects and
organ recipients and in none of the 132 seronegative subjects
matched by age and sex to positive subjects and randomly selected
from the pool of negatives. Two subjects showed a high HHV-8
copy number, one patient with a T-cell lymphoma (copy number
per 106 cells¼ 305 882), who was coinfected with HIV and one
subject HIV negative with a B-cell lymphoma NOS, who had been
previously diagnosed with MCD (copy number per 106
cells¼ 24 444).
DISCUSSION
In our study, no overall differences in the HHV-8 prevalence could
be found between cases and controls. However, HHV-8 was
strongly associated with two subgroups, a four-fold increased risk
of lymphoplasmacytic lymphoma and a five-fold increased risk of
low-grade B-cell lymphoma and B-cell lymphoma NOS. The
detection of HHV-8 DNA in PBMC showed that only one in seven
seropositive subjects had viral DNA detectable in blood. A possible
aetiologic association with HHV-8 was suspected in two subjects
with a very high viral DNA copy number in PBMC. One was an
HIV-positive subject with a T-cell lymphoma. This observation is
in agreement with a recent case report of a PEL of T-cell origin
associated with HHV-8 was suggested in an HIV-negative patient
(Lechapt-Zalcman et al, 2001). The other subject was a B-cell
lymphoma NOS with a previous diagnosis of MCD, suggesting that
HHV-8 in this case is likely to play an aetiological role. This
observation is in agreement with other reports where MCD has
also been associated with other lymphoid neoplasms such as
plasmablastic lymphoma and the recently proposed germinotropic
lymphoproliferative disorder (Du et al, 2001) that involves a
proliferation of plasmablasts.
In our data, we also observed a slight increased risk associated
with HHV-8 for splenic marginal zone lymphomas. These
neoplasms can also harbour plasma cells with cytoplasmatic
immunoglobulins and must be considered within the range of
differential diagnosis of lymphoplasmacytic lymphoma (Whitby
et al, 1995). It has been suggested that HHV-8 could act by
infecting IgM-positive naı¨ve cells and drive these cells to
differentiate into plasmablastic cells without undergoing the
genetic rearrangements that take place within the germinal centre
(Du et al, 2001). Our data are consistent with the hypothesis that
HHV-8 targets B cells before they enter the germinal centre, no
increased risk being observed in our study among plasma cell
neoplasms that involve plasma cells at a more mature stage.
HHV-8 is not readily isolated in cell culture. HHV-8 DNA can be
detected by PCR in all KS tumour biopsies. However, viral DNA is
detectable by nested PCR in the blood in only half of KS patients
and 10% of asymptomatically infected subjects because few
infected cells are present in peripheral blood (Biggar et al, 2003).
Serological assays are considerably more sensitive. Our second-
generation K8.1 ELISA consistently had sensitivity and specificity
values close to 100% (Corchero et al, 2001).
Our case–control study was based on hospitalised patients with
high participation rates for both cases and controls. Serology was
obtained at the time of study entry. A bias in our estimates could
take place if the underlying HHV-8 prevalence of the control
population could affect hospitalisation rates due to HHV-8-related
diseases. Available data from the Spanish general population,
however, indicate that the HHV-8 prevalence ranges between 6 and
8% (Gambus et al, 2001; de Sanjose et al, 2002), which is similar to
the 5.3% observed in our control subjects, and also conforms to
the moderate prevalence observed in Mediterranean countries.
Owing to small numbers in some lymphoma categories, we cannot
exclude that some of the results are due to chance.
Overall, our results suggest that HHV-8 is unlikely to contribute
importantly to lymphomagenesis. The association with lympho-
plasmacytic lymphoma and with low-grade lymphoma deserves
further research.
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